Hydrazine and Dialysis Clearance
There is no direct evidence available regarding hydrazine removal by hemodialysis. Based on the physicochemical properties of hydrazine (low molecular weight ~32 Da, water-soluble, minimal protein binding), it would theoretically be dialyzable, but clinical data are absent from the medical literature.
Clinical Context and Evidence Gap
The provided evidence focuses exclusively on:
- Tuberculosis medications and their dialyzability 1
- Salicylate poisoning management with extracorporeal treatment 2
- Ethylene glycol poisoning and dialysis 3
- General principles of drug removal in hemodiafiltration 4, 5
None of these sources address hydrazine specifically.
Theoretical Considerations
Based on general dialysis principles:
Factors favoring dialyzability:
- Very low molecular weight (32 Da) - well below the typical cutoff for high-flux dialysis membranes
- Water solubility
- Likely minimal protein binding given its chemical structure
Factors requiring consideration:
- Volume of distribution unknown in humans
- Tissue distribution patterns unclear
- Potential for rapid metabolism (as suggested by hepatic and renal toxicity patterns 6, 7)
Practical Clinical Approach
If managing hydrazine toxicity:
Contact a poison control center immediately - this is an uncommon exposure requiring expert consultation
Consider hemodialysis for severe poisoning based on:
- Presence of hepatorenal failure 6
- Theoretical dialyzability based on molecular properties
- Lack of alternative specific antidotes
Monitor closely:
- Hepatic function (transaminases, coagulation, encephalopathy)
- Renal function (creatinine, urine output)
- Metabolic parameters
Supportive care remains primary:
- Aggressive fluid resuscitation
- Correction of coagulopathy
- Management of hepatic encephalopathy if present
Critical Caveat
The absence of published data on hydrazine dialyzability means any decision to pursue extracorporeal treatment must be made in consultation with toxicology and nephrology specialists, weighing the theoretical benefits against the risks and resource utilization of dialysis in the individual clinical context. The decision should be driven primarily by the severity of organ dysfunction (particularly hepatorenal failure) rather than any confirmed efficacy of toxin removal.